The problem with cephalosporins

Journal of Antimicrobial Chemotherapy

Volumn 48, Issue 4, 2001, Pages 463-478

  Dancer, S J ^a  

^a NHS GREATER GLASGOW AND CLYDE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; CEPHALOSPORIN DERIVATIVE; METICILLIN; PENICILLIN G; VANCOMYCIN;

ANIMAL CELL; ANTIBIOTIC RESISTANCE; ANTIMICROBIAL THERAPY; ARTICLE; BACTERIAL GROWTH; BACTERIAL INFECTION; BACTERIUM EXAMINATION; BACTERIUM IDENTIFICATION; CANDIDA ALBICANS; CLOSTRIDIUM DIFFICILE; COAGULASE NEGATIVE STAPHYLOCOCCUS; COLIFORM BACTERIUM; DEVELOPED COUNTRY; DRUG ACTIVITY; DRUG FORMULARY; DRUG HYPERSENSITIVITY; DRUG SCREENING; DRUG USE; ENTEROCOCCUS; HOSPITAL; HOSPITAL INFECTION; HUMAN; INFECTION CONTROL; MEDICAL ASSESSMENT; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIOLOGICAL EXAMINATION; NONHUMAN; PATHOGENICITY; PATIENT CARE; PENICILLIN RESISTANCE; PHYSICIAN; PRESCRIPTION; REVIEW; RISK ASSESSMENT; STREPTOCOCCUS PNEUMONIAE; SUPERINFECTION; TIME;

EID: 0034757437     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/48.4.463     Document Type: Article

References (218)

1. Mechanisms of resistance to β-lactam antibiotics
2. β-Lactams: Cephalosporins
3. Cephalosporins as risk factors for nosocomial Enterococcus faecalis bacteraemia. A matched case-control study
4. Emergence of Enterococcus as a significant pathogen
5. Impact of voluntary vs enforced compliance of third-generation cephalosporin use in a teaching hospital
6. Trends in antimicrobial utilization at a tertiary teaching hospital during a 15 year period (1978-1992)
7. Prior antimicrobial therapy and resistance of Enterobacter, Citrobacter and Serratia to third generation cephalosporins
8. Clinical consequences of development of resistance to third generation cephalosporins
9. Cephalosporin therapeutics for intensive care infections
10. Comparison of organisms carried on the hands of hospital (ICV) personnel and non-medical control personnel
11. Resistant coagulase-negative Staphylococci in hospital patients
12. Dynamics of coagulase-negative staphylococcal colonisation in patients and employers in a surgical intensive care unit
13. Relation of the inanimate environment to endemic nosocomial infections
14. Increased resistance among Staphylococcus epidermidis isolates in a large teaching hospital over a 12-year period
15. Correlations between consumption of antibiotics and methicillin-resistance in coagulase-negative staphylococci
16. Rapid emergence of resistant coagulase-negative staphylococci on the skin after antibiotic prophylaxis
17. Alteration of staphylococcal flora in cardiac surgery patients receiving antibiotic prophylaxis
18. Low-level colonization of hospitalised patients with methicillin-resistant coagulase-negative staphylococci and emergence of the organisms during surgical antimicrobial prophylaxis
19. A model of bacterial-antimicrobial interactions: The case of oropharyngeal and gastro-intestinal microflora
20. Activity of cephalosporins against coagulase-negative staphylococci
21. Antibiotic susceptibility of staphylococci isolated in blood cultures in relation to consumption in hospital wards
22. Methicillin-resistant Staphylococcus epidermidis in infection of hip arthroplasties
23. Staphylococcus epidermidis: A significant nosocomial pathogen
24. Impact of central venous catheter removal on the recurrence of catheter-related coagulase-negative staphylococcal bacteremia
25. The role of cephalosporins in surgical prophylaxis
26. Methicillin-resistant staphylococci in clean surgery. Is there a role for prophylaxis?
27. Prophylaxis in orthopaedic implant surgery-should we use a glycopeptide?
28. Recommendations for preventing the spread of vancomycin resistance
29. MRSA clinical strain with reduced vancomycin susceptibility
30. The effect of cefuroxime axetil on the faecal flora of healthy volunteers
31. Emergence of ceftriaxone-resistant strains of Pseudomonas aeruginosa in cystic fibrosis patients
32. A 25-year study of nosocomial bacteremia in an adult intensive care unit
33. The current and future impact of antimicrobial resistance among nosocomial bacterial pathogens
34. Cephalexin for susceptible bacteriuria in afebrile, long-term catheterized patients
35. Nosocomial infections due to Xanthomonas maltophilia (Pseudomonas maltophilia) in patients
36. An epidemic spread of multi-resistant Pseudomonas aeruginosa in a cystic fibrosis centre
37. Microbiological and clinical aspects of infection associated with Stenotrophomonas maltophilia
38. Extended-spectrum β-lactamases in Pseudomonas aeruginosa
39. Ciprofloxacin resistance among nosocomial Pseudomonas aeruginosa and Staphylococcus aureus in the United States. National Nosocomial Infections Surveillance (NNIS) System
40. Cefepime: Overview of activity in vitro and in vivo
41. The relationship between an increase in β-lactamase activity after oral administration of three new cephalosporins and protection against intestinal ecological disturbances
42. Susceptibility of enterococci and epidemiology of enterococcal infection in the 1980s
43. Nosocomial enterococcal infections: Association with use of third-generation cephalosporin antibiotics
44. Influence of cephalosporins III generation with varying biliary excretion on faecal flora and emergence of resistant bacteria during and after cessation of therapy
45. Overgrowth of Enterococcus faecium in the feces of patients with hematologic malignancies
46. Bacterial resistance
47. Colonisation resistance of the digestive tract - Mechanism and clinical consequences
48. Effect of intramuscular ceftriaxone on aerobic oral and faecal flora of 11 healthy volunteers
49. Choice of antibiotic and risk of colonization with vancomycin-resistant Enterococcus among patients admitted for treatment of community-acquired pneumonia
50. Effect of beta-lactam antibiotics on the resistance of the digestive tract of mice to colonization
51. Selective decontamination of the digestive tract with oral aztreonam and temocillin
52. Antimicrobial resistance amongst enterococci isolated in the United Kingdom, a reference laboratory perspective
53. Vancomycin-resistant enterococci
54. Clostridium difficile: A high-cost nosocomial pathogen
55. The influence of single dose intravenous antibiotics on faecal flora and emergence of Clostridium difficile
56. Third generation cephalosporins as a risk factor for Clostridium difficile-associated disease: A four-year survey in a general hospital
57. Increased risk of diarrhoea caused by Clostridium difficile in elderly patients receiving cefotaxime
58. Presence of Clostridium difficile and antibiotic and beta-lactamase activities in faeces of volunteers treated with oral cefixime, oral cefpodoxime proxetil, or placebo
59. Nosocomial acquisition of Clostridium difficile infection
60. Antimicrobial association of an outbreak of diarrhoea due to Clostridium difficle
61. Financial burden of hospital-acquired infection
62. Incidence and impact of Clostridium difficile infection in the UK, 1993-1996
63. Guidelines for the management of community acquired pneumonia in adults admitted to hospital
64. The role of antimicrobial agents in the etiology of Clostridium difficile-associated disease
65. Community-acquired pneumonia in elderly people
66. The effect of an enhanced infection-control policy on the incidence of Clostridium difficile infection and methicillin-resistant Staphylococcus aureus colonization in acute elderly medical patients
67. Successful control of Clostridium difficile infection in an elderly care unit through use of a restrictive antibiotic policy
68. Risk factors for nosocomial candidemia: A case-control study in adults without leukaemia
69. Risk factors for hospital-acquired candidaemia. A matched case-control study
70. Candida albicans gastro-intestinal colonization and invasion in the mouse: Effect of antibacterial dosing, antifungal therapy and immunosuppression
71. Anti-biotics affecting gastrointestinal colonization of mice by yeasts
72. Effect of cefamandole, cefuroxime and cefoxitin on yeast fecal flora of surgical patients
73. Current management of funguria
74. Candiduria as an early marker of disseminated infection in critically ill surgical patients: The role of fluconazole therapy
75. Epidemiology of Candida infections
76. Epidemiology of candidiasis
77. Secular trends in nosocomial primary bloodstream infections in the United States, 1980-1989
78. Trends in species distribution and susceptibility to fluconazole among blood stream isolates of Candida species in the United States
79. Major trends in the microbial etiology of nosocomial infection
80. Hospital-acquired infections: Diseases with increasingly limited therapies
81. Decrease in expenditures and selected nosocomial infections following implementation of an antimicrobial-prescribing improvement program
82. Cefepime monotherapy for the empirical treatment of fever in granulocytopenic cancer patients
83. A review of the role of antibiotic policies in the control of antibiotic resistance
84. Beta-lactamases
85. Isolation and characterization of coliforms from glacial ice and water in Canada's High Arctic
86. Clinical significance of beta-lactamase induction and stable depression in Gram-negative rods
87. Extended-spectrum β-lactamases: The role of inhibitors in therapy
88. Emergence of resistance in Gram-negative bacilli during beta-lactam therapy: A challenge for the future
89. Molecular and genetic characterization of extended-spectrum beta-lactamases in clinical isolates of Klebsiella pneumoniae
90. Plasmid-mediated beta-lactamases responsible for penicillin and cephalosporin resistance
91. Genetics of extended-spectrum beta-lactamases
92. In-vivo selection of resistance to multiple cephalosporins by Enterobacter cloacae
93. A seven-year survey of antibiotic susceptibility and its relationship with usage
94. The changing ecology of hospital bacteria and the selective role of cephalosporins
95. Inducible β-lactamases: Clinical and epidemiological implications for use of newer cephalosporins
96. Enterobacter bacteremia: Clinical feature and emergence of resistance during therapy
97. Trends in antibiotic utilization and bacterial resistance
98. Treatment failure due to extended-spectrum β-lactamases
99. Antibiotic resistance: Experience at the University of Iona Hospitals and Clinics
100. Outbreak of ceftazidime resistance caused by extended-spectrum β-lactamases at a Massachusetts chronic-care facility
101. Nosocomial outbreak of Klebsiella infection resistant to late-generation cephalosporins
102. Clinical significance of extended-spectrum β-lactamases
103. The relationship between the hospital and the community
104. Resistant bacteria and infection control in the nursing home and hospital
105. Antimicrobial resistance to Streptococcus pneumoniae: An overview
106. Antimicrobial resistance of Streptococcus pneumoniae recovered from outpatients in the United States during the winter months of 1994-1995: Results of a thirty-centre national surveillance study
107. Emergence of multiply resistant pneumococci
108. In vitro selective antibiotic concentrations of beta-lactams for penicillin-resistant Streptococcus pneumoniae populations
109. Penicillin-resistant Streptococcus pneumoniae: Selection by β-lactam and non β-lactam antibiotics
110. Prevalence of antibiotic resistance in pneumococci is higher in Merseyside
111. Predictive factors for invasive disease due to penicillin resistant Streptococcus pneumoniae: A population based study
112. A review of antibiotic resistant patterns of S. pneumoniae in Europe
113. Genetics and molecular biology of β-lactam resistant pneumococci
114. In-vitro activity of 21 β-lactam antibiotics against penicillin-susceptible and penicillin-resistant Streptococcus pneumoniae
115. In-vitro, in-vivo and ex-vivo studies with oral β-lactams against Streptococcus pneumoniae
116. Trends in antibiotic resistance of respiratory pathogens: An analysis and commentary on collaborative surveillance study
117. Single dose ceftriaxone (CRO) for acute otitis media in areas with high resistance to Streptococcus pneumoniae
118. Risk factors for carriage of drug resistant Streptococcus pneumoniae among children in Memphis, Tennessee
119. Factors associated with middle ear isolates of Streptococcus pneumoniae resistant to penicillin in a children's hospital
120. Penicillin-resistant systemic pneumococcal infections in children: A retrospective case-control study
121. Anti-microbial susceptibility of 278 streptococcal blood isolates to seven antimicrobial agents
122. Susceptibility of Streptococcus pneumoniae strains isolated in Italy to penicillin and ten other antibiotics
123. The management of infections and antibiotic therapy: A European survey
124. Effects of cefixime or co-amoxiclav treatment on nasopharyngeal carriage of Streptococcus pneumoniae and Haemophilus influenzae in children with acute otitis media
125. In vitro selection of one-step mutants of S. pneumoniae resistant to different oral β-lactams antibiotics is associated with alterations of PBP2x
126. Antibakterielle Aktivitat und β-Laktamase - Stabilitat von elf Oralcephalosporinen
127. Prevalence of antibiotic resistance in pneumococci is higher in Northern Ireland
128. Streptococcus pneumoniae resistance to erythromycin and penicillin in relation to macrolides and β-lactam consumption in Spain (1979-1997)
129. Do antimicrobials increase the drainage rate of penicillin resistant pneumococci in children? Cross sectional prevalence study
130. Pathogens isolated during treatment failures in otitis
131. Resistance to Antibiotics and Other Antimicrobial Agents
132. Staphylococcus aureus bacteraemia: England and Wales
133. Celbenin-resistant staphylococci
134. Post penicillin antibiotics: From acceptance to resistance?
135. The progressive intercontinental spread of MRSA
136. Gentamicin-methicillin-resistant Staphylococcus aureus: Epidemiology and containment of an outbreak
137. Consideration on MRSA infections in relation to modern chemotherapy
138. Expression and inducibility of methicillin resistance encoded by a mecA gene in staphylococci
139. Influences of type and duration of antimicrobial prophylaxis on an outbreak of methicillin-resistant Staphylococcus aureus and on the incidence of wound infection
140. The carrier state: Methicillin resistant Staphylococcus aureus
141. Methicillin-resistant Staphylococcus aureus in Europe
142. Staphylococcus aureus. Pan-European antibiotic resistance and infection control
143. Community acquired MRSA infections: A new source for nosocomial outbreaks
144. Methicillin resistance in staphylococci: Molecular and biochemical basis and clinical implications
145. Mechanism of β-lactam-resistance in MRSA
146. Emergence of methicillin-resistant clones from cephamycin-resistant Staphylococcus aureus
147. Risk factors for methicillin-resistant S. aureus (MRSA) infection in a Japanese elderly care nursing home
148. An outbreak of infections caused by strains of Staphylococcus aureus resistant to methicillin and aminoglycosides
149. Risk factors for methicillin-resistant Staphylococcus aureus (MRSA) infection in a Japanese geriatric hospital
150. Methicillin-resistant Staphylococcus aureus: Introduction and spread within a hospital
151. Genesis of methicillin-resistant Staphylococcus aureus (MRSA), how treatment of MRSA infections has selected for vancomycin-resistant Enterococcus faecium, and the importance of antibiotic management and infection control
152. Development of staphylococci cross-resistant to cephalexin and methicillin
153. Selection of β-lactamase producers during cephalosporin and penicillin therapy
154. Evolution of antibiotic resistance in Staphylococcus aureus: The role of the skin
155. Transfer of resistant plasmids from Staphylococcus epidermidis to Staphylococcus aureus: Evidence for conjugate exchange of resistance
156. Dissemination among staphylococci of DNA sequences associated with methicillin resistance
157. Guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever
158. The acquisition of antibiotic resistant coagulase-negative staphylococci by aortic graft recipients
159. Colonization and infection with methicillin-resistant Staphylococcus aureus: Associated factors and eradication
160. Antibiotic usage and methicillin-resistant Staphylococci aureus: An analysis of casualty
161. Decreased antimicrobial resistance after changes in antibiotic use
162. Dutch measures to control MRSA and the expanding European Union
163. Four pediatric deaths from community-acquired MRSA - Minnesota and North Dakota, 1997-1999
164. Methicillin-resistant staphylococcaemia: Bacteriological failure of treatment with cephalosporins
165. Resistance of methicillin-resistant Staphylococcus aureus to third-generation cephalosporins
166. In vitro activity of ceftriaxone on hospital bacteria. Results of a multicenter study
167. Association of borderline oxacillin-susceptible strains of Staphylococcus aureus with surgical wound infections
168. Vancomycin-dependent enterococci: Curious phenomenon or serious threat?
169. Multi drug resistant Enterococcus faecium. An untreatable nosocomial pathogen
170. The control of hyperendemic glycopeptide-resistant Enterococcus spp. on a haematology unit by changing antibiotic usage
171. The treatment and control of vancomycin-resistant enterococci
172. The emergence of Enterococcus faecium resistant to glycopeptides and other standard agents - A preliminary report
173. Report of a meeting on the epidemiology and control of glycopeptide-resistant enterococci
174. High prevalence of colonization with vancomycin- and pristinamycin-resistant enterococci in healthy humans and pigs in The Netherlands: Is the addition of antibiotics to animal feeds to blame?
175. Glycopeptide-resistant Enterococcus faecium outside hospitals: A commentary
176. The challenge of vancomycin-resistant enterococci: A clinical and epidemiologic study
177. Treatment of infections due to methicillin-resistant Staphylococcus aureus
178. Oral vancomycin for antibiotic-associated pseudo-membranous colitis
179. Detection of glycopeptide-resistant enterococci in routine diagnostic faeces specimens
180. Phenotypic and genotypic heterogeneity of glycopeptide resistance determinants in gram-positive bacteria
181. Vancomycin-resistant enterococci at a large university hospital in Denmark
182. Epidemiology and control of vancomycin-resistant enterococci in an adult and children's hospital
183. Impact of a vancomycin restriction policy on use and cost of vancomycin and incidence of vancomycin-resistant Enterococcus
184. Enterococci resistant to multiple antimicrobial agents, including vancomycin. Establishment of endemicity in a university medical center
185. Vancomycin-resistant and vancomycin-susceptible enterococci on dry surfaces
186. Mopping up hospital infection
187. Outbreak of vancomycin-resistant enterococci in a hospital in Gdansk, Poland, due to horizontal transfer of different Tn1546-like transposon variants and clonal spread of several strains
188. Bacterial flora of the hospital environment: Identification, susceptibility to disinfecting agents, antibiotics and chemotherapeutics
189. Co-transfer of vancomycin and other resistance genes from Enterococcus faecalis NCTC 12201 to Staphylococcus aureus
190. Transferable vancomycin and teicoplanin resistance in Enterococcus faecium
191. Activated cell-wall synthesis is associated with vancomycin resistance in methicillin-resistant Staphylococcus aureus clinical strains Mu3 and Mu50
192. Post-antibiotic effect of β-lactam antibiotics on gram-negative bacteria in relation to morphology, initial killing and MIC
193. Forty years of β-lactam research
194. Effect of β-lactam antibiotics on bacterial cell growth rate
195. Involvement of penicillin-binding protein 2 with other penicillin-binding proteins in lysis of Escherichia coli by some β-lactam antibiotics alone and in synergistic lytic effect of amdinocillin (mecillinam)
196. The response of Entero-bacteriaceae to β-lactam antibiotics-'round forms, filaments and the root of all evil'
197. Antibiotic induced release of endotoxin: A reappraisal
198. Effects of different types and combinations of antimicrobial agents on endotoxin release from Gram-negative bacteria: An in-vitro and in-vivo study
199. The effects of plasmid-mediated cephalosporinases and endotoxins on septic patients
200. Serial quantitation of endotoxemia and bacteremia during therapy for Gram-negative sepsis
201. New criteria for selecting the proper antimicrobial chemotherapy for severe sepsis and septic shock
202. Antibiotic resistance
203. Non-hospital consumption of antibiotics in Spain: 1987-1997
204. Do intensive hospital antibiotic control programs prevent the spread of antibiotic resistance?
205. Guidelines for the prevention of antimicrobial resistance in hospitals. Society for Health-care Epidemiology of America and Infectious Diseases Society of America Joint Committee on the Prevention of Antimicrobial Resistance
206. Interaction between the microbiology laboratory and clinician: What the microbiologist can provide
207. Recent advances in curtailing costs of antimicrobial agents
208. Control of antibiotic use in the United Kingdom
209. Colonization of resistant faecal aerobic Gram-negative bacilli among geriatric patients in hospital and the community
210. Microbes, chemotherapy, evolution, and folly
211. A survey of undergraduate and continuing medical education and about antimicrobial chemotherapy in the United Kingdom
212. Third generation cephalosporins: Safety profiles after 10 years of clinical use
213. Antimicrobiological prophylaxis in surgery; microbiological factors
214. Epidemiology of antibiotic resistance
215. Antibiotic resistance in the ICU; the eve of destruction
216. Efficacy and safety of recombinant human activated protein C for severe sepsis
217. Afelimomab